SCHEMBL1507923

SCHEMBL1507923

N#CC(c1ccc(F)cc1)(c1ccc(F)cc1)C(c1ccccc1)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 4/20 0.41
LMNA P02545 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
NPSR1 Q6W5P4 2/20 0.41
HPGD P15428 2/20 0.41
ALDH1A1 P00352 2/20 0.41
USP2 O75604 1/20 0.41
CYP2D6 P10635 5/20 0.39
CYP3A4 P08684 3/20 0.39
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
NPC1 O15118 2/20 0.38
ALPG P10696 1/20 0.37
KCNN4 O15554 2/20 0.36
SLC6A4 P31645 3/20 0.36
TRPA1 O75762 1/20 0.34
TSHR P16473 1/20 0.34
MAPT P10636 2/20 0.33
KMT2A Q03164 2/20 0.33
SLC6A2 P23975 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1507842 0.88 KCNN4 (0.41) HTTLMNASMN1; SMN2NPSR1HPGD
SCHEMBL1059119 0.87 CYP2D6 (0.49) ALDH1A1CYP2D6CYP3A4CYP2C19KCNN4
SCHEMBL1059122 0.87 CYP2D6 (0.49) ALDH1A1CYP2D6CYP3A4CYP2C19KCNN4
SCHEMBL14229957 0.77 KCNN4 (0.43) HTTLMNASMN1; SMN2NPSR1HPGD
SCHEMBL1507914 0.75 CYP3A4 (0.41) HTTLMNASMN1; SMN2ALDH1A1USP2
SCHEMBL1443801 0.72 KCNN4 (0.47) HTTLMNASMN1; SMN2NPSR1HPGD
SCHEMBL2392348 0.72 KCNN4 (0.47) HTTLMNASMN1; SMN2NPSR1HPGD
SCHEMBL14229953 0.72 KCNN4 (0.43) HTTNPSR1CYP2D6CYP3A4CYP2C9
SCHEMBL1508072 0.71 KCNN4 (0.43) NPSR1ALDH1A1CYP2D6CYP3A4NPC1
SCHEMBL27532534 0.68 CYP2D6 (0.54) HTTHPGDALDH1A1USP2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1911740-A1 POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2008-04-16 EP claimed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US claimed
US-20050009816-A1 Potassium channel modulators SANIONA A/S (DK) 2005-01-13 US claimed
EP-1465863-A1 POTASSIUM CHANNEL MODULATORS Poseidon Pharmaceuticals A/S (DK) 2004-10-13 EP claimed
WO-2003059873-A1 POTASSIUM CHANNEL MODULATORS POSEIDON PHARMACEUTICALS A/S (DK) 2003-07-24 WO claimed
EP-2292595-A1 Potassium channel modulators NeuroSearch AS (DK) 2011-03-09 EP disclosed
EP-2292595-A1 Potassium channel modulators NeuroSearch AS (DK) 2011-03-09 EP disclosed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US disclosed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US disclosed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US disclosed
EP-1911740-A1 POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2008-04-16 EP disclosed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US disclosed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US disclosed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US disclosed
US-7208527-B2 Potassium channel modulators POSEIDON PHARMACEUTICALS A/S (DK) 2007-04-24 US disclosed
US-7208527-B2 Potassium channel modulators POSEIDON PHARMACEUTICALS A/S (DK) 2007-04-24 US disclosed
US-7208527-B2 Potassium channel modulators POSEIDON PHARMACEUTICALS A/S (DK) 2007-04-24 US disclosed
US-20050009816-A1 Potassium channel modulators SANIONA A/S (DK) 2005-01-13 US disclosed
EP-1465863-A1 POTASSIUM CHANNEL MODULATORS Poseidon Pharmaceuticals A/S (DK) 2004-10-13 EP disclosed
WO-2003059873-A1 POTASSIUM CHANNEL MODULATORS POSEIDON PHARMACEUTICALS A/S (DK) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009816-A1 Potassium channel modulators KCNC1, KCNQ1, KCNA1 HTT 1226/4885LMNA 2815/4885SMN1; SMN2 3752/4885
US-20070161607-A1 Potassium channel modulators KCNC1, KCNQ1, KCNA1 HTT 1226/4885LMNA 2815/4885SMN1; SMN2 3752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.